Sector Expert: Dennis Hulme

Edison Investment Research

Dennis Hulme joined Edison's healthcare team in November 2014 after almost 10 years covering the healthcare and agriculture sectors as an analyst at BBY Stockbrokers. Previously, he worked as a research scientist with CSIRO and the University of Sydney. Dr. Hulme has a Ph.D. in veterinary science from the University of Sydney.

Subscribe to
Streetwise Reports

Companies Commented On

  • Adherium Ltd.
  • Mesoblast Ltd.
  • Prima BioMed Ltd.
  • Regeneus Ltd.
  • Viralytics Ltd.


Recent Interviews

Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology (5/11/16)
australiamedicine630

Biotech and medtech startups are not confined to the U.S. and Europe. Unmet medical needs exist all over the globe, and they create a powerful vacuum that sucks in bright minds and risk-taking capitalists. Australia is a good example: The regulatory environment supports first-in-human experimentation and entrepreneurship. Healthcare Analyst Dennis Hulme of Edison Investment Research is headquartered in Sydney, and in this interview with The Life Sciences Report, he cites a group of Australian medtech and biotech names that investors should look at very carefully.

Recent Quotes

"RGS will seek wider applications of Progenza beyond osteoarthritis."

— Dennis Hulme, Edison Investment Research (2/16/17)
more >

"Our valuation of RGS increases with the AGC cash and larger addressable market in Japan partly offset by longer timelines and revised assumptions for CryoShot and Kvax."

— Dennis Hulme, Edison Investment Research (1/27/17)
more >

"Cancer immunotherapy, including cancer vaccines such as RGS' RGSH4K, is a biotech hotspot."

— Dennis Hulme, Edison Investment Research (12/8/16)
more >

"RGS has firmed up its strategy to partner its product opportunities for development and commercialization, allowing it to focus on early-stage product development."

— Dennis Hulme, Edison Investment Research (11/17/16)
more >

"RGS anticipates entering a binding arrangement with a manufacturing and commercialisation partner."

— Dennis Hulme, Edison Investment Research (9/14/16)
more >

"Cancer immunotherapy, including cancer vaccines such as RGS' RGSH4K, is a biotech hotspot."

— Dennis Hulme, Edison Investment Research (8/18/16)
more >

"RGS aims to finalize manufacturing and clinical development partnerships in Japan in Q2/16."

— Dennis Hulme, Edison Investment Research (6/23/16)
more >

"RGS positive safety review augurs well for the company's plan to secure a manufacturing and commercial partner for Progenza in Japan."

— Dennis Hulme, Edison Investment Research (5/19/16)
more >

more comments

"MESO revealed the Phase III trial of Revascor in CHF cleared its first interim safety analysis."

— Dennis Hulme, Edison Investment Research (5/11/16)
more >

"There is strong potential RGS will strike a commercialization deal in Japan sometime this year; that's going to be the key driver."

The Life Sciences Report Interview with Dennis Hulme (5/11/16)
more >

"RGS aims to finalize partnerships in Japan in Q2/16."

— Dennis Hulme, Edison Investment Research (3/24/16)
more >

"RGS is developing and commercializing its adipose-derived mesenchymal stem cell technology for musculoskeletal conditions in animals and humans."

— Dennis Hulme, Edison Investment Research (2/25/16)
more >

"RGS partnered with a veterinary pharma to develop CryoShot Canine."

— Dennis Hulme, Edison Investment Research (12/2/15)
more >

"RGS has been involved in discussions with potential partners."

— Dennis Hulme, Edison Investment Research (9/9/15)
more >

"RGS is poised to become a player in the buoyant immuno-oncology space."

— Dennis Hulme, Edison Investment Research (4/17/15)
more >

fewer comments


Due to permission requirements, not all quotes are shown.